Both hemostatic plug formation and thrombosis require thrombin-dependent fibrin formation, platelet recruitment and aggregation. While hemostasis is an essential process, pathologic thrombosis can cause stroke, heart attack and other vasoocclusive diseases. Coagulation factors XI and XII (FXI, FXII) promote thrombin generation through the coagulation cascade. We found that both FXI and FXII contribute to experimental thrombosis, and epidemiologic data suggest that FXI deficiency is protective against deep vein thrombosis and ischemic stroke. Yet, unlike other coagulation factors, FXI-deficiency causes only a mild hemostasis disorder and FXII deficiency is apparently asymptomatic without a demonstrable role for FXII in normal hemostasis. Our original findings have opened a new window towards the development of new safe antithrombotic strategies. In this renewal application of my first R01 grant, we address the major unresolved questions on the role of FXI in thrombus formation, including activities that bypass the FIX- mediated intrinsic thrombin generation pathway. We will test our hypothesis that FXI also plays a key role in promoting thrombin generation through the inactivation of local endogenous anticoagulants.
In Aim 1 we will characterize the mechanisms by which FXI-platelet crosstalk promotes the procoagulant activities of platelets during thrombus formation. We will test our hypothesis that FXIa promotes the clot formation through the inactivation of platelet tissue factor pathway inhibitor (TFPI).
In Aim 2 we will define the role of FXIa in the prothrombotic activities of neutrophil extracellular traps (NETs), and will determine whether activation of the contact pathway by NETs promotes platelet activation and microaggregate formation distal to sites of thrombus formation under flow.
In Aim 3 we will utilize in vitro and in vivo models to define the molecular mechanisms by which FXI promotes tissue factor-dependent coagulation on endothelial cells. The goal of the proposed studies is to better understand the role of contact activation in the initiation and propagation of thrombus formation, which may provide further rationale for therapeutic targeting of the FXI axis as a safer new strategy to combat thrombosis.

Public Health Relevance

Despite the significant advances in cardiovascular medicine, heart attacks and strokes that are caused by thrombosis (blood clots) remain the leading causes of severe chronic morbidity and mortality in the US. To better combat these diseases, an ideal antithrombotic agent should selectively target molecular events that support the formation of intravascular clot formation without affecting processes that help control bleeding upon injury. We found that pharmacologic targeting of the contact activation of blood may achieve this goal, and now propose in depth investigation of the mechanistic roles that enzymes of the contact activation pathway, including coagulation factors XI and XII, may play in pathologic clot formation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL101972-08
Application #
9241431
Study Section
Special Emphasis Panel (ZRG1-VH-B (03)M)
Program Officer
Warren, Ronald Q
Project Start
2010-04-01
Project End
2019-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
8
Fiscal Year
2017
Total Cost
$442,968
Indirect Cost
$152,305
Name
Oregon Health and Science University
Department
Engineering (All Types)
Type
Schools of Medicine
DUNS #
096997515
City
Portland
State
OR
Country
United States
Zip Code
97239
Healy, Laura D; Rigg, Rachel A; Griffin, John H et al. (2018) Regulation of immune cell signaling by activated protein C. J Leukoc Biol :
Rigg, Rachel A; Healy, Laura D; Chu, Tiffany T et al. (2018) Protease-activated receptor 4 activity promotes platelet granule release and platelet-leukocyte interactions. Platelets :1-10
Mitrugno, Annachiara; Sylman, Joanna L; Rigg, Rachel A et al. (2018) Carpe low-dose aspirin: the new anti-cancer face of an old anti-platelet drug. Platelets 29:773-778
Tillman, Benjamin F; Gruber, Andras; McCarty, Owen J T et al. (2018) Plasma contact factors as therapeutic targets. Blood Rev 32:433-448
Zilberman-Rudenko, Jevgenia; Reitsma, St├ęphanie E; Puy, Cristina et al. (2018) Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. Arterioscler Thromb Vasc Biol 38:1748-1760
Ngo, Anh T P; McCarty, Owen J T; Aslan, Joseph E (2018) TRPing out Platelet Calcium: TRPM7 (Transient Receptor Potential Melastatin-Like 7) Modulates Calcium Mobilization and Platelet Function via Phospholipase C Interactions. Arterioscler Thromb Vasc Biol 38:285-286
Rocheleau, Anne D; Khader, Ayesha; Ngo, Anh T P et al. (2018) Pilot study of novel lab methodology and testing of platelet function in adolescent women with heavy menstrual bleeding. Pediatr Res 83:693-701
Zilberman-Rudenko, Jevgenia; Zhao, Frank Z; Reitsma, Stephanie E et al. (2018) Effect of Pneumatic Tubing System Transport on Platelet Apheresis Units. Cardiovasc Eng Technol 9:515-527
Mitrugno, Annachiara; Rigg, Rachel A; Laschober, Nicole B et al. (2018) Potentiation of TRAP-6-induced platelet dense granule release by blockade of P2Y12 signaling with MRS2395. Platelets 29:383-394
Sylman, Joanna L; Boyce, Hunter B; Mitrugno, Annachiara et al. (2018) A Temporal Examination of Platelet Counts as a Predictor of Prognosis in Lung, Prostate, and Colon Cancer Patients. Sci Rep 8:6564

Showing the most recent 10 out of 82 publications